ESH AL 2024 | Therapy-related ALL: etiology, prognosis, and treatment
Caner Saygin, MD, University of Chicago, Chicago, IL, discusses therapy-related acute lymphoblastic leukemia (ALL), often triggered by genotoxic therapy like lenalidomide for multiple myeloma (MM). Patients with this type of ALL exhibit a higher-risk profile and a less favorable prognosis compared to de novo ALL, particularly in achieving measurable residual disease (MRD) negativity. Treatment for therapy-related ALL includes transplantation, which should be guided by MRD status, and antibodies such as blinatumomab and inotuzumab ozogamicin, which are currently being evaluated in clinical trials. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
